title: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial

acronym: WAKE-UP

summary: WAKE-UP is an investigator initiated European multicenter randomized controlled clinical trial of MRI based thrombolysis in acute stroke patients with unknown time of symptom onset, e.g. due to recognition of stroke symptoms on awakening. Objective of WAKE-UP is to prove efficacy and safety of MRI-based intravenous thrombolysis with Alteplase in patients waking up with stroke symptoms or patients with otherwise unknown symptom onset.

ReferenceCitation: Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Günther M, Guibernau J, Häusler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez de la Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C; WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018 Aug 16;379(7):611-622. doi: 10.1056/NEJMoa1804355. Epub 2018 May 16.

name: From Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg–Eppendorf (G.T., B. Cheng, S.G., A.G., C.G.), the Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg–Eppendorf (J.F.), and ZytoService Deutschland (E.S.), Hamburg, Universitätsklinik für Neurologie, Medizinische Universität Graz, Graz (F.F.), Centrum für Schlaganfallforschung Berlin (I.G., K.G.H., K.V., M. Ebinger, M. Endres, J.B.F.) and Klinik und Hochschulambulanz...

family: Thomalla

full_name: Götz Thomalla

given: Götz

family: Simonsen

full_name: Claus Z. Simonsen

given: Claus Z.

family: Boutitie

full_name: Florent Boutitie

given: Florent

family: Andersen

full_name: Grethe Andersen

given: Grethe

family: Berthezene

full_name: Yves Berthezene

given: Yves

family: Cheng

full_name: Bastian Cheng

given: Bastian

family: Cheripelli

full_name: Bharath Cheripelli

given: Bharath

family: Cho

full_name: Tae-Hee Cho

given: Tae-Hee

family: Fazekas

full_name: Franz Fazekas

family: Fiehler

full_name: Jens Fiehler

given: Jens

family: Ford

full_name: Ian Ford

given: Ian

family: Galinovic

full_name: Ivana Galinovic

given: Ivana

family: Gellissen

full_name: Susanne Gellissen

given: Susanne

family: Golsari

full_name: Amir Golsari

given: Amir

family: Gregori

full_name: Johannes Gregori

given: Johannes

family: Günther

full_name: Matthias Günther

given: Matthias

family: Guibernau

full_name: Jorge Guibernau

given: Jorge

family: Häusler

full_name: Karl Georg Häusler

given: Karl Georg

family: Hennerici

full_name: Michael Hennerici

family: Kemmling

full_name: André Kemmling

given: André

family: Marstrand

full_name: Jacob Marstrand

given: Jacob

family: Modrau

full_name: Boris Modrau

given: Boris

family: Neeb

full_name: Lars Neeb

given: Lars

repository_institution: The University of Glasgow - Enlighten: Publications

repositories_institution: The University of Glasgow - Enlighten: Publications

title: MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

ReferenceCitation: Schlemm L, Braemswig TB, Boutitie F, Vynckier J, Jensen M, Galinovic I, Simonsen CZ, Cheng B, Cho TH, Fiehler J, Puig J, Thijs V, Fiebach J, Muir K, Nighoghossian N, Ebinger M, Pedraza S, Thomalla G, Gerloff C, Endres M, Lemmens R, Nolte CH; WAKE-UP Investigators. Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial. Neurology. 2021 Nov 15. pii: 10.1212/WNL.0000000000013055. doi: 10.1212/WNL.0000000000013055. [Epub ahead of print]

ReferenceCitation: Lettow I, Jensen M, Schlemm E, Boutitie F, Quandt F, Cheng B, Ebinger M, Endres M, Fiebach JB, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G; WAKE-UP Investigators. Serious Adverse Events and Their Impact on Functional Outcome in Acute Ischemic Stroke in the WAKE-UP Trial. Stroke. 2021 Dec;52(12):3768-3776. doi: 10.1161/STROKEAHA.120.033425. Epub 2021 Aug 26.

name: Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germany (I.L., M.J., E.S., F.Q., B.C., C.G., G.T.).

name: Hospices Civils de Lyon, Service de Biostatistique, France (F.B.).

name: Klinik für Neurologie, Medical Park Berlin Humboldtmühle, Germany (M. Ebinger).

name: entrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Germany (M. Ebinger, M. Endres, J.B.F.).

name: Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Germany (M. Endres).

name: Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (V.T.).

name: Austin Health, Department of Neurology, Australia (V.T.).

name: Department of Neurology, University Hospitals Leuven, Belgium (R.L.).

name: KU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology, Belgium (R.L.).

name: VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Campus Gasthuisberg, Belgium (R.L.).

name: Institute of Neuroscience & Psychology, University of Glasgow, University Avenue, Glasgow G12 8QQ, United Kingdom (K.W.M.).

name: Department of Stroke Medicine, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, France (N.N.).

name: Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d’Investigació Biomèdica de Girona (IDIBGI), Parc Hospitalari Martí i Julià de Salt - Edifici M2, Italysa (S.P.).

name: Department of Neurology, Aarhus University Hospital, Denmark (C.Z.S.).

ReferenceCitation: Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, Fiebach JB, Fiehler J, Nickel A, Puig J, Roy P, Lemmens R, Thijs V, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G. 24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke. Eur Stroke J. 2021 Jun;6(2):168-175. doi: 10.1177/23969873211014758. Epub 2021 Jun 18.

name: Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

name: Hospices Civils de Lyon, Service de Biostatistique, Lyon, France

name: Centrum für Schlaganfallforschung Berlin (CSB), Charité – Universitätsmedizin Berlin, Berlin, Germany

name: Medical Park Berlin Humboldtmühle, Klinik für Neurologie, Berlin, Germany

name: Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany

name: Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

name: Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d’Investigació Biomèdica de Girona (IDIBGI), Parc Hospitalari Martí i Julià de Salt - Edifici M2, Girona, Spain

name: Department of Neurology, University Hospitals Leuven, Leuven, Belgium

name: KU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology, Leuven, Belgium

name: VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium

name: Austin Health, Department of Neurology, Heidelberg, Australia

name: Institute of Neuroscience & Psychology, University of Glasgow, University Avenue, Glasgow, UK

name: Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

ReferenceCitation: Scheldeman L, Wouters A, Dupont P, Christensen S, Boutitie F, Cheng B, Ebinger M, Endres M, Fiebach JB, Gerloff C, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Ringelstein EB, Chamorro A, Grond M, Laage R, Schneider A, Thomalla G, Thijs V, Lemmens R. Reversible Edema in the Penumbra Correlates With Severity of Hypoperfusion. Stroke. 2021 Jul;52(7):2338-2346. doi: 10.1161/STROKEAHA.120.033071. Epub 2021 May 13.

name: Department of Neurology, University Hospitals Leuven, Belgium (L.S., A.W., R. Lemmens).

name: Department of Neurosciences, Experimental Neurology (L.S., A.W., R. Lemmens), KU Leuven–University of Leuven, Belgium.

name: Center for Brain and Disease Research, Laboratory of Neurobiology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium (L.S., A.W., R. Lemmens).

name: Department of Neurosciences, Laboratory for Cognitive Neurology (P.D.), KU Leuven–University of Leuven, Belgium.

name: GrayNumber Analytics, Lomma, Sweden (S.C.).

name: Université Lyon 1, Villeurbanne, France (F.B.).

name: Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germany (B.C., C.G., G.T.).

name: Center for Stroke Research Berlin (M. Ebinger, M. Endres, J.B.F.), Charité–Universitätsmedizin Berlin, Germany.

name: Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité–Universitätsmedizin Berlin, Germany.

name: German Center for Cardiovascular Research, Partner Site Berlin (M. Endres).

name: German Center for Neurodegenerative Diseases, Partner Site Berlin (M. Endres).

name: ExcellenceCluster “NeuroCure” (M. Endres).

name: Institute of Neuroscience and Psychology, University of Glasgow, United Kingdom (K.W.M.).

name: Department of Stroke Medicine, Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, Hospices Civils de Lyon, France (N.N.).

name: Department of Radiology, Institut de Diagnostic per la Image, Hospital Dr Josep Trueta, Institut d’Investigació Biomedica de Girona, Parc Hospitalari Marti i Julia de Salt–Edifici M2, Spain (S.P.).

name: Department of Neurology, University of Münster, Germany (E.B.R.).

name: Stroke Centre, University of Barcelona, Spain (A.C.).

name: Kreisklinikum Siegen GmbH, Germany (M.G.).

name: GUIDED Development Heidelberg GmbH, Germany (R. Laage).

name: Lifedatascience Consulting, Schriesheim, Germany (A.S.).

name: Stroke Theme, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia (V.T.).

name: Department of Neurology, Austin Health, Heidelberg, Victoria, Australia (V.T.).

title: Reversible Edema in the Penumbra Correlates With Severity of Hypoperfusion

ReferenceCitation: Königsberg A, Sehner S, Arlt S, Cheng B, Simonsen CZ, Boutitie F, Serena J, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C, Thomalla G; WAKE-UP investigators. Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial. Eur J Neurol. 2021 Jun;28(6):2017-2025. doi: 10.1111/ene.14797. Epub 2021 Mar 22.

name: Klinik und Poliklinik für Neurologie Kopf‐ und Neurozentrum Universitätsklinikum Hamburg‐Eppendorf Hamburg Germany

name: Institut für Medizinische Biometrie und Epidemiologie Zentrum für Experimentelle MedizinUniversitätsklinikum Hamburg‐Eppendorf Hamburg Germany

name: Department of Psychiatry and Psychotherapy Evangelical Hospital Alsterdorf Hamburg Germany

name: Department of Neurology Aarhus University Hospital Aarhus Denmark

name: Service de Biostatistique Centre d'Investigation Clinique Hospices Civils de Lyon Lyon France

name: Department of Neurology Hospital Universitario Dr Josep TruetaInstitut d'Investigació Biomèdica de Girona Girona Spain

name: Stroke Division Florey Institute of Neuroscience and Mental Health University of Melbourne Heidelberg Victoria Australia

name: Department of Neurology Austin Health Heidelberg Victoria Australia

name: Centrum für Schlaganfallforschung Berlin (CSB) Charité‐Universitätsmedizin Berlin Berlin Germany

name: Klinik für Neurologie Medical Park Berlin Humboldtmühle Berlin Germany

name: Klinik und Hochschulambulanz für NeurologieCharité‐Universitätsmedizin Berlin Berlin Germany

name: Exzellenz Cluster Neuro Cure, Charité‐Universitätsmedizin Berlin, Berlin, Germany, DZHK, partner site Berlin, DZNE, partner site Berlin Berlin Germany

name: Department of Neurology University Hospitals Leuven Leuven Belgium

name: Vesalius Research CenterVIB Leuven Belgium

name: Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND) University of Leuven Leuven Belgium

name: Institute of Neuroscience and Psychology University of Glasgow Glasgow UK

name: Department of Neurology Hospices Civils de Lyon Lyon France

name: Department of Radiology Institut de Diagnostic per la Image (IDI) Hospital Dr Josep TruetaInstitut d’Investgació Biomèdica de Girona (IDIBGI) Girona Spain

repository_normalized: University of Melbourne - Minerva Access

repository_institution: Universitat de Girona - Universitat de Girona Digital Repository

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

repositories: University of Melbourne - Minerva Access

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes

repositories_institution: Universitat de Girona - Universitat de Girona Digital Repository

repositories_institution: University of Melbourne - Minerva Access

title: Effect of intravenous alteplase on post‐stroke depression in the WAKE UP trial

ReferenceCitation: Grosch AS, Kufner A, Boutitie F, Cheng B, Ebinger M, Endres M, Fiebach JB, Fiehler J, Königsberg A, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Siemonsen CZ, Thijs V, Wouters A, Gerloff C, Thomalla G, Galinovic I. Extent of FLAIR Hyperintense Vessels May Modify Treatment Effect of Thrombolysis: A Post hoc Analysis of the WAKE-UP Trial. Front Neurol. 2021 Feb 4;11:623881. doi: 10.3389/fneur.2020.623881. eCollection 2020.

repository_institution: Universitätsbibliothek der Freien Universität Berlin - Refubium

repositories_institution: Universitätsbibliothek der Freien Universität Berlin - Refubium

ReferenceCitation: Barow E, Pinnschmidt H, Boutitie F, Königsberg A, Ebinger M, Endres M, Fiebach JB, Fiehler J, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G, Cheng B; WAKE-UP investigators. Symptoms and probabilistic anatomical mapping of lacunar infarcts. Neurol Res Pract. 2020 Aug 3;2:21. doi: 10.1186/s42466-020-00068-y. eCollection 2020.

title: Symptoms and probabilistic anatomical mapping of lacunar infarcts

ReferenceCitation: Schlemm L, Kufner A, Boutitie F, Nave AH, Gerloff C, Thomalla G, Simonsen CZ, Ford I, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Ebinger M, Endres M. Current Smoking Does Not Modify the Treatment Effect of Intravenous Thrombolysis in Acute Ischemic Stroke Patients-A Post-hoc Analysis of the WAKE-UP Trial. Front Neurol. 2019 Nov 22;10:1239. doi: 10.3389/fneur.2019.01239. eCollection 2019.

title: Current Smoking Does Not Modify the Treatment Effect of Intravenous Thrombolysis in Acute Ischemic Stroke Patients—A Post-hoc Analysis of the WAKE-UP Trial

ReferenceCitation: Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, Fiebach JB, Fiehler J, Ford I, Galinovic I, Nickel A, Puig J, Roy P, Wouters A, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G; WAKE-UP investigators. Clinical Characteristics and Outcome of Patients with Lacunar Infarcts and Concurrent Embolic Ischemic Lesions. Clin Neuroradiol. 2020 Sep;30(3):511-516. doi: 10.1007/s00062-019-00800-5. Epub 2019 Jun 3.

ReferenceCitation: Thomalla G, Boutitie F, Fiebach JB, Simonsen CZ, Nighoghossian N, Pedraza S, Lemmens R, Roy P, Muir KW, Heesen C, Ebinger M, Ford I, Cheng B, Cho TH, Puig J, Thijs V, Endres M, Fiehler J, Gerloff C. Effect of informed consent on patient characteristics in a stroke thrombolysis trial. Neurology. 2017 Sep 26;89(13):1400-1407. doi: 10.1212/WNL.0000000000004414. Epub 2017 Aug 25.

title: Effect of informed consent on patient characteristics in a stroke thrombolysis trial

ReferenceCitation: Thomalla G, Boutitie F, Fiebach JB, Simonsen CZ, Pedraza S, Lemmens R, Nighoghossian N, Roy P, Muir KW, Ebinger M, Ford I, Cheng B, Galinovic I, Cho TH, Puig J, Thijs V, Endres M, Fiehler J, Gerloff C. Clinical characteristics of unknown symptom onset stroke patients with and without diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch. Int J Stroke. 2018 Jan;13(1):66-73. doi: 10.1177/1747493017706245. Epub 2017 Apr 20.

name: Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

name: Centrum für Schlaganfallforschung Berlin (CSB), Charité—Universitätsmedizin Berlin, Berlin, Germany

name: Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d’Investgació Biomèdica de Girona (IDIBGI), Girona, Spain

name: KU Leuven—University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium

name: University Hospitals Leuven, Department of Neurology, Leuven, Belgium

name: Department of Neurology, Hospices Civils de Lyon, Lyon, France

name: Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, UK

name: Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

name: Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia

name: Department of Neurology, Austin Health, Heidelberg, Australia

name: Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Diagnostikzentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

ReferenceCitation: Thomalla G, Boutitie F, Fiebach JB, Simonsen CZ, Nighoghossian N, Pedraza S, Lemmens R, Roy P, Muir KW, Ebinger M, Ford I, Cheng B, Galinovic I, Cho TH, Puig J, Thijs V, Endres M, Fiehler J, Gerloff C; WAKE-UP Investigators. Stroke With Unknown Time of Symptom Onset: Baseline Clinical and Magnetic Resonance Imaging Data of the First Thousand Patients in WAKE-UP (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke: A Randomized, Doubleblind, Placebo-Controlled Trial). Stroke. 2017 Mar;48(3):770-773. doi: 10.1161/STROKEAHA.116.015233. Epub 2017 Feb 7.

name: From the Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum (G.T., B.C., C.G.) and Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Diagnostikzentrum (J.F.), Universitätsklinikum Hamburg-Eppendorf, Germany; Service de Biostatistique, Hospices Civils de Lyon, France (F.B., P.R.); Université Lyon 1, Villeurbanne, France (F.B., P.R.); CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France (F.B., P.R.); Centrum...

title: Stroke With Unknown Time of Symptom Onset

location_country:
France
Belgium
Spain
Denmark
Germany
United Kingdom

location_facility: Aarhus Universitetshospital, Aahrhus Sygehus

location_facility: Institut d'Investigacio Biomedica de Girona Doctor Josep Trueta

location_facility: University Medical Center Hamburg-Eppendorf


type: Other Identifier

title: AURA Study: A Retrospective Non-interventional Study (NIS) to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (wAMD)

acronym: AURA

summary: Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

status: Completed

study_completion_date_type: Actual

study_type: Observational

time_perspective: Retrospective

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016 Dec;100(12):1623-1628. doi: 10.1136/bjophthalmol-2015-308166. Epub 2016 Mar 30.

family: Holz

full_name: Frank G Holz

given: Frank G

sequence: first

family: Tadayoni

full_name: Ramin Tadayoni

given: Ramin

sequence: additional

family: Beatty

full_name: Stephen Beatty

given: Stephen

family: Berger

full_name: Alan Berger

given: Alan

family: Cereda

full_name: Matteo Giuseppe Cereda

given: Matteo Giuseppe

family: Hykin

full_name: Philip Hykin

given: Philip

family: Staurenghi

full_name: Giovanni Staurenghi

given: Giovanni

family: Wittrup-Jensen

full_name: Kim Wittrup-Jensen

given: Kim

family: Altemark

full_name: Andreas Altemark

given: Andreas

family: Nilsson

full_name: Jonas Nilsson

given: Jonas

family: Kim

full_name: Kun Kim

given: Kun

family: Sivaprasad

full_name: Sobha Sivaprasad

given: Sobha

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: British Journal of Ophthalmology

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: open (via page says license)

host_type: publisher

license: cc-by-nc

license_normalized: cc-by-nc

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via pmcid lookup)

license_normalized: no license

publisher: BMJ

publisher_dissemination: British Medical Journal

publisher_group: British Medical Journal

publisher_normalized: British Medical Journal

ReferenceCitation: Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015 Feb;99(2):220-6. doi: 10.1136/bjophthalmol-2014-305327. Epub 2014 Sep 5.

evidence: oa repository (via OAI-PMH title and first author match)

repositories_institution:
PubMed Central - Europe PMC
Radboud University - Radboud Repository

location_country:
Italy
Netherlands
France
Japan
Venezuela
Ireland
Australia
Germany
United Kingdom
Canada


title: A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects

summary: The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method of for the correction of presbyopia in patients who have normal distance vision but need correction such as glasses or contact lenses to see clearly at near.

study_type: Interventional

primary_purpose: Treatment

ipd_sharing: No

lead_sponsor: AcuFocus, Inc.

location_country:
Austria
Netherlands
Philippines
France
Japan
Singapore
Australia
New Zealand
Spain
Turkey

location_facility: Univ. Klinik fur Agugenheilkunde und Optometrie, Paracelsus Medzinishe Privatuniversitat Salzburg

location_facility: Beyoğlu Goz Training and Research Hospital

intervention_type: Device

lead_sponsor_type: industriel

status_simplified: Completed


type: EudraCT Number

title: A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-term Follow-up

summary: Comparison of tacrolimus blood levels in adults who have received a transplant and are taking either Prograf or Advagraf anti-rejection therapy immediately following surgery. This is followed by checking of safety and effectiveness for one year.

design_allocation: Randomized

primary_purpose: Prevention

lead_sponsor: Astellas Pharma Inc

location_country:
Italy
Austria
France
Belgium
United Kingdom
Taiwan

intervention_type: Drug


title: Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) Used in the Differentiation of Focal Pancreatic Masses

summary:
The aim of the study is to assess the accuracy of real-time perfusion imaging pattern of pancreatic focal lesions visualized by contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) for the differential diagnosis between chronic pseudotumoral pancreatitis and pancreatic cancer in a prospective multicenter design.

The study will include patients with focal pancreatic masses evaluated by CEH-EUS and EUS-FNA. The diagnosis is usually unknown in the moment of the initial evaluation, the patients being included based on a suspicion of focal pancreatic masses after transabdominal ultrasound, CT or MR examinations. However, after a complete evaluation, a final diagnosis will be reached based on the combination of EUS-FNA cytology/pathology, surgical pathology and minimum 12 months follow-up.

time_perspective: Prospective

ReferenceType: background

ReferenceCitation: Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D'Onofrio M, Evans DH, Filice C, Greiner L, Jäger K, Jong Nd, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, Nolsøe C, Piscaglia F, Ricci P, Seidel G, Skjoldbye B, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med. 2008 Feb;29(1):28-44. doi: 10.1055/s-2007-963785.

ReferenceCitation: Seicean A, Badea R, Stan-Iuga R, Gulei I, Pop T, Pascu O. The added value of real-time harmonics contrast-enhanced endoscopic ultrasonography for the characterisation of pancreatic diseases in routine practice. J Gastrointestin Liver Dis. 2010 Mar;19(1):99-104.

ReferenceCitation: Hocke M, Schulze E, Gottschalk P, Topalidis T, Dietrich CF. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterol. 2006 Jan 14;12(2):246-50.

ReferenceCitation: Săftoiu A, Iordache SA, Gheonea DI, Popescu C, Maloş A, Gorunescu F, Ciurea T, Iordache A, Popescu GL, Manea CT. Combined contrast-enhanced power Doppler and real-time sonoelastography performed during EUS, used in the differential diagnosis of focal pancreatic masses (with videos). Gastrointest Endosc. 2010 Oct;72(4):739-47. doi: 10.1016/j.gie.2010.02.056. Epub 2010 Aug 2.

ReferenceCitation: Seicean A. Endoscopic ultrasound in chronic pancreatitis: where are we now? World J Gastroenterol. 2010 Sep 14;16(34):4253-63. Review.

ReferenceCitation: Dietrich CF, Ignee A, Frey H. Contrast-enhanced endoscopic ultrasound with low mechanical index: a new technique. Z Gastroenterol. 2005 Nov;43(11):1219-23.

ReferenceCitation: Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O. Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med. 2010 Dec;31(6):571-6. doi: 10.1055/s-0029-1245833. Epub 2010 Nov 15.

ReferenceCitation: Săftoiu A, Vilmann P, Dietrich CF, Iglesias-Garcia J, Hocke M, Seicean A, Ignee A, Hassan H, Streba CT, Ioncică AM, Gheonea DI, Ciurea T. Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). Gastrointest Endosc. 2015 Jul;82(1):59-69. doi: 10.1016/j.gie.2014.11.040. Epub 2015 Mar 16.

family: Săftoiu

full_name: Adrian Săftoiu

given: Adrian

family: Vilmann

full_name: Peter Vilmann

given: Peter

family: Dietrich

full_name: Christoph F. Dietrich

given: Christoph F.

family: Iglesias-Garcia

full_name: Julio Iglesias-Garcia

given: Julio

family: Hocke

full_name: Michael Hocke

given: Michael

family: Seicean

full_name: Andrada Seicean

given: Andrada

family: Ignee

full_name: Andre Ignee

given: Andre

family: Hassan

full_name: Hazem Hassan

given: Hazem

family: Streba

full_name: Costin Teodor Streba

given: Costin Teodor

family: Ioncică

full_name: Ana Maria Ioncică

given: Ana Maria

family: Gheonea

full_name: Dan Ionuţ Gheonea

given: Dan Ionuţ

family: Ciurea

full_name: Tudorel Ciurea

given: Tudorel

journal_name: Gastrointestinal Endoscopy

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

lead_sponsor: University of Medicine and Pharmacy Craiova

location_country:
Italy
France
Norway
Romania
Spain
Denmark
Germany
United Kingdom

location_facility: Department of Surgical Gastroenterology, Gentofte & Herlev Hospital, University of Copenhagen

location_facility: Institute of Hepatology, University College London

location_facility: Department of Internal Medicine II, Hospital Meiningen

location_facility: University Hospital, Santiago de Compostela

location_facility: Gastroenterology and Gastrointestinal Endoscopy Unit, Vita Salute San Raffaele University

location_facility: Helios Klinikum, University of Witten/Herdecke

location_facility: Hepatobiliary Surgery, Glasgow Royal Infirmary

location_facility: Insitute of Medicine, University of Bergen and National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital

location_facility: Center for Surgical Ultrasound, Department of Surgery, Odense University Hospital

location_facility: Center of Gastroenterology and Hepatology, Fundeni Clinical Institute

location_facility: Gastroenterology Department, University of Medicine and Pharmacy

lead_sponsor_type: academique


title: Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy

acronym: IMPACT

summary: This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after first-line standard chemotherapy regimens.

lead_sponsor: Mologen AG

location_country:
Austria
United Kingdom
France
Russian Federation
Germany
Czech Republic

location_facility: Klinik für Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie, Universitätsklinikum Giessen und Marburg GmbH

location_facility: State Institution "Russian Scientific Oncology Center named after N.N. Blokhin RAMN"

location_facility: Medizinische Klinik, Abteilung für Onkologie, Hämatologie Immunologie, Rheumatologie und Pulmologie Universität Tübingen, Immuntherapie, Station 65 Med. Klinik Abt. II

location_facility: Onkologischer Schwerpunkt am Oskar-Helene-Heim

location_facility: Non-state health care institution "Central Clinical Hospital No. 2 named after N.A. Semashko OAO "RZHD"

location_facility: Klinik für Innere Medizin IV, Onkologie/ Hämatologie/ Hämostaseologie, Universitätsklinikum Halle (Saale)

location_facility: Oncology Clinic, Faculty Hospital Olomouc

location_facility: Kath. Marienkrankenhaus GmbH, Allgemeine Onkologie

location_facility: Service de Cancérologie Digestive, Institut de Cancérologie Gustave Roussy

location_facility: Schwerpunktpraxis für Hämatologie und Onkologie

location_facility: Klinik für Innere Medizin I, Abteilung für Klinische Onkologie, Medizinische Universität Wien


title: Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials

acronym: TALISMAN S

summary: The objective of this study is to collect retrospectively long term safety data in patients who have participated in the previous phase I-II trials conducted with the compound.

lead_sponsor: Sanofi

location_country:
Italy
United States
Switzerland
France
Belgium
Germany
United Kingdom


title: Malnutrition and Outcome in Hospitalized Children in Europe (ESPEN Network Grant Project)

summary:
Malnutrition in children has even more severe consequences on disease course and long-term health than malnutrition in adults. According to prior studies, malnutrition affects about 15-30 % of hospitalized children in Europe (ESPGHAN 2005, Pawellek et al 2008, Joosten and Hulst 2008). However, available criteria for defining malnutrition in paediatric patients are inconsistent, not based on firm evidence, and not generally agreed upon. Current guidelines do not address assessment of and screening for childhood malnutrition. Therefore, a large number of affected children are not adequately diagnosed.

One aim of this study is to assess the prevalence of malnutrition and patients at risk for malnutrition among at least 2700 hospitalized children mainly across Europe. In addition criteria to link anthropometric measurements and the prediction of outcome, i.e. length of hospital stay, shall be established. A further goal then is to establish agreed, evidence-based criteria for malnutrition in children with the purpose of leading to an agreed, evidence-based screening tool for paediatric malnutrition in developed countries. This tool shall include a set of simple questions, based on previously suggested tools. Thereby this study will provide a strong basis for implementing evidence-based nutritional interventions in paediatric patients by harmonisation of diagnostic criteria for childhood malnutrition in developed countries.

ReferenceCitation: Chourdakis M, Hecht C, Gerasimidis K, Joosten KF, Karagiozoglou-Lampoudi T, Koetse HA, Ksiazyk J, Lazea C, Shamir R, Szajewska H, Koletzko B, Hulst JM. Malnutrition risk in hospitalized children: use of 3 screening tools in a large European population. Am J Clin Nutr. 2016 May;103(5):1301-10. doi: 10.3945/ajcn.115.110700. Epub 2016 Apr 20.

family: Chourdakis

full_name: Michael Chourdakis

family: Hecht

full_name: Christina Hecht

given: Christina

family: Gerasimidis

full_name: Konstantinos Gerasimidis

given: Konstantinos

family: Joosten

full_name: Koen FM Joosten

given: Koen FM

family: Karagiozoglou-Lampoudi

full_name: Thomais Karagiozoglou-Lampoudi

given: Thomais

family: Koetse

full_name: Harma A Koetse

given: Harma A

family: Ksiazyk

full_name: Janusz Ksiazyk

given: Janusz

family: Lazea

full_name: Cecilia Lazea

given: Cecilia

family: Shamir

full_name: Raanan Shamir

given: Raanan

family: Szajewska

full_name: Hania Szajewska

given: Hania

family: Koletzko

full_name: Berthold Koletzko

given: Berthold

family: Hulst

full_name: Jessie M Hulst

given: Jessie M

journal_name: The American Journal of Clinical Nutrition

evidence: open (via free article)

version: acceptedVersion

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

publisher_normalized: Oxford University Press

ReferenceCitation: Hecht C, Weber M, Grote V, Daskalou E, Dell'Era L, Flynn D, Gerasimidis K, Gottrand F, Hartman C, Hulst J, Joosten K, Karagiozoglou-Lampoudi T, Koetse HA, Kolaček S, Książyk J, Niseteo T, Olszewska K, Pavesi P, Piwowarczyk A, Rousseaux J, Shamir R, Sullivan PB, Szajewska H, Vernon-Roberts A, Koletzko B. Disease associated malnutrition correlates with length of hospital stay in children. Clin Nutr. 2015 Feb;34(1):53-9. doi: 10.1016/j.clnu.2014.01.003. Epub 2014 Jan 11.

family: Weber

full_name: Martina Weber

given: Martina

family: Grote

full_name: Veit Grote

given: Veit

family: Daskalou

full_name: Efstratia Daskalou

given: Efstratia

family: Dell'Era

full_name: Laura Dell'Era

given: Laura

family: Flynn

full_name: Diana Flynn

given: Diana

lead_sponsor: Ludwig-Maximilians - University of Munich

location_country:
Italy
Netherlands
Croatia
France
Greece
Israel
Poland
Romania
Denmark
Germany
United Kingdom

location_facility: The Children's Memorial Health Institute

location_facility: Paediatric Clinical Investigation Center Unit (CIC-9301-Inserm-CHU) and U995-Inserm, hospital Jeanne de Flandre, University hospital of Lille.

location_facility: Rigshospitalet, Copenhagen University Hospital

location_facility: Sophia Children's Hospital, Erasmus University

location_facility: Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Milano

location_facility: Beatrix Children's Hospital, University Medical Center Groningen

location_facility: Dr. von Hauner Children's Hospital. Munich, Germany


title: A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)

acronym: SHIELD

summary: A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

status: Terminated

lead_sponsor: Novartis Pharmaceuticals

location_country:
United States
Jordan
Hong Kong
France
Greece
Israel
Tunisia
Singapore
Egypt
Spain
Turkey
Germany
Korea, Republic of
Taiwan

status_simplified: Unknown


title: Evaluation of Safety and Effectiveness of the Formula PTX Balloon-Expandable Stent for Renal Artery Stenosis

summary: The purpose of the study is to evaluate the safety and effectiveness of the PTX-coating on the Formula PTX Balloon-Expandable Stent in treatment of renal artery stenosis.

lead_sponsor: Cook Group Incorporated

location_country:
Germany
United Kingdom
France
Czechia

location_facility: Institute for Clinical and Experimental Medicine

location_facility: Klinik Dr. Hancken im Elbe Klinikum Stade


title: A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.

summary: This is an Extension study of the MICONOS main randomised placebo-controlled trial (NCT00905268), and open to those patients completing the main study. The scientific aim of this extension study is to monitor safety and tolerability of idebenone over two years in patients with Friedreich's Ataxia.

lead_sponsor: Santhera Pharmaceuticals

location_country: Austria Netherlands France Belgium Germany

location_facility: Hôpital de la Salpétrière - INSERM U679, Neurologie et Thérapeutique expérimentale

location_facility: Neurologische Universitätsklinik und Poliklinik

location_facility: UKE Hamburg Neuropädiatrie - Zentrum für Frauen, Kinder und Jugendmedizin

location_facility: Hôpital Erasme - Univeristé Libre de Bruxelles

location_facility: Neurologische Universitätsklinik und Ploklinik - Universitätsklimikum Bonn

location_facility: Klinik II, Neuropädiatrie und Muskelerkrankungen - Universitätsklinik Freiburg

location_facility: Neurologische Klinik - Klinikum Grosshadern


title: A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over

summary: This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study. Eligible subjects will undergo an open-label, single-dose acute hemodynamic study with ACT-293987(NS-304) and 21 weeks of double-blind treatment during which subjects will receive either ACT-293987 (NS-304) or placebo b.i.d. Subjects who have completed the double-blind study can enter the open extension study (separate protocol) and receive administration of ACT-293987 (NS-304) if the subject wishes and the Investigator considers it appropriate.

ReferenceCitation: Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80. Epub 2012 Feb 23.

lead_sponsor: Actelion

location_country:
Italy
Austria
France
Poland
Hungary
Belgium
Germany
United Kingdom

location_facility: Instytut Gruzilcy i Chorob Pluc, Klinika Chorob Wewnetrznych Klatki Piersiowej

location_facility: Medizinische Universitat Wien, Universitatsklinik fur Innere Medizin II, Kardiologie

location_facility: Hospital Sant'Orsola Malpighi, Cardiology's Department

location_facility: Gasthuisberg University Hospital, Pneumology

location_facility: Department of Respiratory Medicine, Hannover Medical School

location_facility: Semmelweis University, Clinic of Pulmonology


title: A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg & 12.5 mg) in Patients With Sore Throat

summary:
Primary Objective:

To compare the single-dose efficacy of ketoprofen lysinate lozenges (6.25 mg and 12.5 mg ketoprofen base) with placebo, on total pain relief summed over 15 to 120 min (TOTPAR15-120) after the first intake of study drug.

Secondary Objectives:

To compare the single-dose efficacy of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) with placebo after the first intake on:

the total pain relief summed over 15 to 360min (TOTPAR15-360)
the changes from baseline of global throat pain intensity assessed over 15 to 120min and over 15 to 360min.
the changes from baseline of throat soreness over 15 to 120min and over 15 to 360min
the changes from baseline of swollen throat over 15 to 120min and over 15 to 360min To compare pain relief, global throat pain intensity, throat soreness and swollen throat in the evening of days 1, 2 and 3

To evaluate the safety of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) and placebo at follow-up visit on:

Day 4: - adverse events and clinical examination Day 7: - adverse events reporting (followed by a clinical examination if needed)

location_country:
Mexico
Finland
France
Russian Federation
Egypt
Spain
Germany


title: A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

acronym: MICONOS

summary: The purpose of this trial is to study the efficacy, safety and tolerability of idebenone in 12 months of treatment in children and adults with Friedreich's Ataxia. This is a randomised placebo-controlled double-blind trial conducted in Europe. Efficacy outcomes include measures of neurological impairment and function, and measures of the heart.

location_country:
Austria
Netherlands
France
Belgium
Germany
United Kingdom

location_facility: UKE Hamburg Neuropädiatrie-Zentum für Frauen, Kinder und Jugendmedizin

location_facility: National Hospital for Neurology & Neurosurgery

location_facility: Hôpital Erasme - Université Libre de Bruxelles

location_facility: University of Newcastle upon Tyne -Mitochondrial Research Group

location_facility: Neurologische Universitätsklinik und Poliklinik- Universitätsklinikum Bonn

location_facility: Neurologische Klinik- klinikum Grosshadern

location_facility: Klinik II, Neuropädiatrie u.Muskelerkrankungen- Universitätsklinik Freiburg

location_facility: Hôpital de la Salpêtrière - INSERM U679, Neurologie et Thérapeutique expérimentale


intervention_type: Biological

lead_sponsor: Stallergenes Greer

location_country:
Sweden
Finland
France
Poland
Lithuania
Russian Federation
Denmark
Germany

location_facility: NHC, Hôpitaux Universitaires de Strasbourg

location_facility: Public Institution Kaunas Medical University Hospital

location_facility: SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi

location_facility: National University Hospital - Allergy Unit 4222

source: euctr

title: A Multi-national, Randomised, DBPC, Phase II Study to Assess the Efficacy and Safety of Three Doses of SLIT Administered as rBet v 1 Tablets Once Daily to Patients Suffering From Birch Pollen Rhinoconjunctivitis

summary: The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.


acronym: IRIS

summary: This study will assist in the early detection of influenza resistant to antivirals and will monitor the clinical outcome of adults and children infected with influenza according to subtype and susceptibility. Participants clinically diagnosed with influenza will undergo a rapid diagnostic test and viral sampling at Baseline and on Days 3, 6, and 10. Participants will be clinically managed according to local guidelines and the decision to treat/not treat will be at the discretion of the Investigator.

ReferenceCitation: Roosenhoff R, Reed V, Kenwright A, Schutten M, Boucher CA, Monto A, Clinch B, Kumar D, Whitley R, Nguyen-Van-Tam JS, Osterhaus ADME, Fouchier RAM, Fraaij PLA. Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clin Infect Dis. 2020 Aug 22;71(5):1186-1194. doi: 10.1093/cid/ciz939.

name: Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands

family: Roosenhoff

full_name: Rueshandra Roosenhoff

given: Rueshandra

name: Micron Research Ltd, Ely, United Kingdom

family: Reed

full_name: Vaughan Reed

given: Vaughan

name: Roche Products Ltd, Welwyn Garden City, United Kingdom

family: Kenwright

full_name: Andy Kenwright

given: Andy

name: Clinical Virology and Diagnostics, Alkmaar, The Netherlands

family: Schutten

full_name: Martin Schutten

given: Martin

family: Boucher

full_name: Charles A Boucher

given: Charles A

name: Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA

family: Monto

full_name: Arnold Monto

given: Arnold

family: Clinch

full_name: Barry Clinch

given: Barry

name: Transplant Infectious Diseases and Multi Organ Transplant Program, University Health Network, Toronto, Ontario, Canada

family: Kumar

full_name: Deepali Kumar

given: Deepali

name: Department of Pediatrics, Microbiology, Medicine, and Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA

family: Whitley

full_name: Richard Whitley

given: Richard

name: School of Medicine, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom

family: Nguyen-Van-Tam

full_name: Jonathan S Nguyen-Van-Tam

given: Jonathan S

name: Research Institute for Infectious Diseases and Zoonosis, University of Veterinary Medicine, Hannover, Germany

name: Artemis One Health Research Institute, Utrecht, The Netherlands

family: Osterhaus

full_name: Albert D M E Osterhaus

given: Albert D M E

family: Fouchier

full_name: Ron A M Fouchier

given: Ron A M

name: Department of Pediatrics, Subdivision Infectious Diseases and Immunology, Erasmus Medical Center–Sophia, Rotterdam, The Netherlands

family: Fraaij

full_name: Pieter L A Fraaij

given: Pieter L A

journal_name: Clinical Infectious Diseases

evidence: open (via crossref license)

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

repository_institution: University of Nottingham - Repository@Nottingham

repository_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

url: https://nottingham-repository.worktribe.com/2723258/1/dv-tam53187 rev1.0 r.roosenhoff irisped manuscript trackchange

url_for_landing_page: https://nottingham-repository.worktribe.com/2723258/1/DV-TAM53187 Rev1.0 R.Roosenhoff IRISPED Manuscript TrackChange

ReferenceCitation: Fraaij PL, Schutten M, Javouhey E, Burleigh L, Outlaw R, Kumar D, Boucher CA. Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS). Antivir Ther. 2015;20(6):633-42. doi: 10.3851/IMP2957. Epub 2015 Apr 7.

full_name: Pieter Fraaij

given: Pieter

title: Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromized patients with influenza in the Influenza Resistance Information Study (IRIS)

location_country:
United States
Hong Kong
Netherlands
France
Poland
Norway
Australia
Germany


title: REal-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra® Therapy

summary: The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction. Furthermore, the data collection particularly focuses on the experience of the patient and his satisfaction with the treatment. Treatment naive patients as well as pre-treated patients will be included in the study.The maximum observation period per patient is 12 months.Besides the physician's documentation, the patient should fill out a questionnaire at every visit. The questionnaires will be handed out and collected by the physician. Furthermore, an additional questionnaire for the patient's partner can be distributed at each visit in case the partner is willing to participate.

lead_sponsor: Bayer

location_country:
South Africa
Sweden
Saudi Arabia
Spain
France
Croatia
Malaysia
Poland
Thailand
Singapore
Hungary
China
Indonesia
Germany
Korea, Republic of


ReferenceCitation: Avlonitis VS, Planas S, Hayes AM, Parry A. Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation. Ann Thorac Surg. 2012 Feb;93(2):656-8. doi: 10.1016/j.athoracsur.2011.07.071.

family: Avlonitis

full_name: Vassilios Spiridon Avlonitis

given: Vassilios Spiridon

family: Planas

full_name: Silvia Planas

given: Silvia

family: Hayes

full_name: Alison M. Hayes

given: Alison M.

family: Parry

full_name: Andrew Parry

given: Andrew

journal_name: The Annals of Thoracic Surgery

title: Occlusion of Modified Blalock-Taussig Shunt After Clopidogrel Cessation

location_country:
Italy
Brazil
India
Mexico
Spain
Germany
France
Malaysia
Poland
Hungary
Russian Federation
Portugal
United States
United Kingdom
Taiwan

acronym: CLARINET LT

title: Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age

summary:
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.

The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patients for whom the shunt was still in place at one year of age.

The secondary objective was to assess the efficacy on the occurrence of shunt thrombosis requiring intervention or any death.


title: A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension

acronym: ACCELERATE

summary: This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.

primary_purpose: Diagnostic

ReferenceCitation: Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.

apc_source: openAPC

family: Brown

full_name: Morris J Brown

given: Morris J

family: Williams

full_name: Bryan Williams

given: Bryan

family: Morant

full_name: Steve V Morant

given: Steve V

family: Webb

full_name: David J Webb

given: David J

family: Caulfield

full_name: Mark J Caulfield

given: Mark J

family: Cruickshank

full_name: J Kennedy Cruickshank

given: J Kennedy

family: Ford

full_name: Ian Ford

given: Ian

family: McInnes

full_name: Gordon McInnes

given: Gordon

family: Sever

full_name: Peter Sever

given: Peter

family: Salsbury

full_name: Jackie Salsbury

given: Jackie

family: Mackenzie

full_name: Isla S Mackenzie

given: Isla S

family: Padmanabhan

full_name: Sandosh Padmanabhan

given: Sandosh

family: MacDonald

full_name: Thomas M MacDonald

given: Thomas M

journal_name: The Lancet Diabetes & Endocrinology

license: cc-by

license_normalized: cc-by

repository_institution: Imperial College London - Spiral

repository_institution: University of Dundee - Discovery Research Portal

repository_institution: King's College London - Research Portal

repository_normalized: Pure (Denmark)

repository_institution: Queen Mary University of London - Queen Mary Research Online

repository_institution: University of Edinburgh - Edinburgh Research Explorer

repository_institution: University College London - UCL Discovery

ReferenceCitation: Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub 2011 Jan 12.

location_country:
South Africa
Guatemala
Costa Rica
Switzerland
France
Greece
Venezuela
Germany
United Kingdom
Canada


title: 28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/70 Bid in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Antidiabetic Drug Treatment.

acronym: LAPTOP

summary: To compare efficacy of combination therapy of insulin glargine plus glimepiride and metformin versus 2 injections insulin monotherapy with premixed insulin NPH 30/70 bid in terms of change of HbA1c (baseline to endpoint) to show non-inferiority of insulin glargine plus glimepiride and metformin.

location_country:
Italy
Austria
Sweden
Switzerland
Netherlands
Finland
France
Spain
Germany
United Kingdom

location_facility:
Sanofi-aventis administrative office
Sanofi aventis administrative office
Sanofi-Aventis Administrative Office


title: A European Phase III, Multicentre, Double-blind, Randomised, Monotherapy, 12-month Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome

summary: Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.

ReferenceCitation: Branco JC, Cherin P, Montagne A, Bouroubi A; Multinational Coordinator Study Group. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol. 2011 Jul;38(7):1403-12. doi: 10.3899/jrheum.101025. Epub 2011 Apr 1.

family: BRANCO

full_name: JAIME C. BRANCO

given: JAIME C.

family: CHERIN

full_name: PATRICK CHERIN

given: PATRICK

family: MONTAGNE

full_name: AGNES MONTAGNE

given: AGNES

family: BOUROUBI

full_name: ATHMANE BOUROUBI

given: ATHMANE

journal_name: The Journal of Rheumatology

publisher: The Journal of Rheumatology

publisher_dissemination: The Journal of Rheumatology

publisher_group: The Journal of Rheumatology

publisher_normalized: The Journal of Rheumatology

title: Longterm Therapeutic Response to Milnacipran Treatment for Fibromyalgia. A European 1-Year Extension Study Following a 3-Month Study

lead_sponsor: Pierre Fabre Medicament

location_country:
Italy
Sweden
Spain
Finland
France
Norway
Romania
Portugal
Germany
Czech Republic

location_facility: KKSK KLINIKUM DER UNIVERSITAET ZU KOELN - Anaesthesiology and Intensive Care


title: Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO)

acronym: ERATO

summary: The purpose of this study is to assess the efficacy of dronedarone for the control of ventricular rate at rest and during exercise in patients with atrial fibrillation (AF) and to assess the tolerability of dronedarone in the target population.

ReferenceType: result

ReferenceCitation: Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008 Sep;156(3):527.e1-9. doi: 10.1016/j.ahj.2008.06.010.

family: Davy

full_name: Jean-Marc Davy

given: Jean-Marc

family: Herold

full_name: Martin Herold

given: Martin

family: Hoglund

full_name: Christer Hoglund

given: Christer

family: Timmermans

full_name: Alphons Timmermans

given: Alphons

family: Alings

full_name: Antonio Alings

given: Antonio

family: Radzik

full_name: David Radzik

given: David

family: Van Kempen

full_name: Louis Van Kempen

given: Louis

journal_name: American Heart Journal

title: Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study

location_country:
Italy
Sweden
Switzerland
Netherlands
France
Poland
Belgium
Spain
Czech Republic


lead_sponsor: AstraZeneca

location_country: Italy France Poland Belgium Germany Ukraine

acronym: HIP

title: An Open-label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: a Long Term Study

summary: The HIP study is designed to follow the clinical experience of young hypertensive children receiving candesartan cilexetil (Atacand) who are between the ages of 1 and less than 11 years old. The study is open label with no concurrent control group. To be eligible for HIP, children must have completed Study 328 without discontinuation due to a study drug-related AE and in the investigator's opinion, have an on-going clinical indication for an orally administered suspension of candesartan cilexetil to control blood pressure. Children will return to clinic every 3 months (more frequently at the investigator's discretion) for safety and efficacy evaluations. Safety will be monitored by serum chemistries, urinalyses, echocardiograms and by physical examinations at specified clinic visits. Blood pressure and heart rate will be measured at each clinic visit. Study drug is administered orally once a day. Investigators determine the efficacious dose ( 0.05 mg/kg; 0.2 mg/kg; 0.4 mg/kg) on a vist-by-vist basis depending on the child's BP response. It is anticipated that study dose will align closely with the effective anti-hypertensive dose determined in Study 328. If the child's hypertension is not well-controlled, dose adjustments up to a maximum of 0.4mg/kg/day and/or the addition of other antihypertensive medications are permitted, with the exception of other angiotensin receptor blockers. The HIP study offers eligible children up to two additional years of treatment with the liquid formulation of Atacand.


title: Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients

acronym: PEITHO

summary: Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients included in those studies is too low. The aim of the study is to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary embolism) in a large group of patients with sub-massive pulmonary embolism.

study_start_date_type: Actual

ReferenceCitation: Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004 Aug 10;110(6):744-9. Epub 2004 Jul 19.

ReferenceCitation: Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2021 Apr 15;4:CD004437. doi: 10.1002/14651858.CD004437.pub6.

name: The Center of Gerontology and Geriatrics; West China Hospital, Sichuan University; Chengdu China

name: National Clinical Research Center for Geriatrics; West China Hospital, Sichuan University; Chengdu China

family: Zuo

full_name: Zhiliang Zuo

given: Zhiliang

family: Yue

full_name: Jirong Yue

given: Jirong

family: Dong

full_name: Bi Rong Dong

given: Bi Rong

name: Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials; West China Hospital, Sichuan University; Chengdu China

family: Wu

full_name: Taixiang Wu

given: Taixiang

name: Cochrane China; West China Hospital, Sichuan University; Chengdu China

family: Liu

full_name: Guan J Liu

given: Guan J

family: Hao

full_name: Qiukui Hao

given: Qiukui

journal_name: Cochrane Database of Systematic Reviews

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

ReferenceCitation: Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039.

family: Konstantinides

full_name: Stavros V. Konstantinides

given: Stavros V.

family: Vicaut

full_name: Eric Vicaut

given: Eric

family: Danays

full_name: Thierry Danays

given: Thierry

family: Becattini

full_name: Cecilia Becattini

given: Cecilia

family: Bertoletti

full_name: Laurent Bertoletti

given: Laurent

family: Beyer-Westendorf

full_name: Jan Beyer-Westendorf

given: Jan

family: Bouvaist

full_name: Helene Bouvaist

given: Helene

family: Couturaud

full_name: Francis Couturaud

given: Francis

family: Dellas

full_name: Claudia Dellas

given: Claudia

family: Duerschmied

full_name: Daniel Duerschmied

given: Daniel

family: Empen

full_name: Klaus Empen

given: Klaus

family: Ferrari

full_name: Emile Ferrari

given: Emile

family: Galiè

full_name: Nazzareno Galiè

given: Nazzareno

family: Jiménez

full_name: David Jiménez

journal_name: Journal of the American College of Cardiology

ReferenceCitation: Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097.

repository_institution: University of Bern - Bern Open Repository and Information System

title: Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

ReferenceCitation: Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J. 2012 Jan;163(1):33-38.e1. doi: 10.1016/j.ahj.2011.10.003.

title: Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial

location_country: Italy Austria Spain France Poland Greece Israel Hungary Belgium Portugal Germany Slovenia

location_facility: Istituto di Cardiologia, Policlinico S.Orsola-MaBologna


title: An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

summary: This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

status: Recruiting

study_completion_date_type: Anticipated

design_allocation: Non-Randomized

enrollment_type: Anticipated

ReferenceCitation: Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin NP, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody. Blood. 2021 Jul 19. pii: blood.2020010477. doi: 10.1182/blood.2020010477. [Epub ahead of print]

name: University Hospital, LMU Munich, Germany

family: Augsberger

full_name: Christian Augsberger

given: Christian

name: University Hospital LMU Munich, Munich, Germany

family: Hänel

full_name: Gerulf Hänel

given: Gerulf

family: Xu

full_name: Wei Xu

given: Wei

name: Roche Pharma Research & Early Development, Schlieren, Switzerland

family: Pulko

full_name: Vesna Pulko

given: Vesna

name: Roche Pharma Research & Early Development, Schlieren, Alabama, Switzerland

family: Hanisch

full_name: Lydia Jasmin Hanisch

given: Lydia Jasmin

name: Roche Pharma Research & Early Development, Basel, Switzerland

family: Augustin

full_name: Angelique Augustin

given: Angelique

family: Challier

full_name: John Challier

given: John

name: Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany

family: Hunt

full_name: Katharina Hunt

given: Katharina

family: Vick

full_name: Binje Vick

given: Binje

name: IRCCS San Raffaele Scientific Institute, Milano, Italy

family: Rovatti

full_name: Pier Edoardo Rovatti

given: Pier Edoardo

family: Krupka

full_name: Christina Krupka

given: Christina

name: Ludwig-Maximilians-Universität München, München, Germany

family: Rothe

full_name: Maurine Rothe

given: Maurine

family: Schönle

full_name: Anne Schönle

given: Anne

family: Sam

full_name: Johannes Sam

given: Johannes

family: Lezan

full_name: Emmanuelle Lezan

given: Emmanuelle

family: Ducret

full_name: Axel Ducret

given: Axel

family: Ortiz-Franyuti

full_name: Daniela Ortiz-Franyuti

given: Daniela

name: Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland, Basel, Switzerland

family: Walz

full_name: Antje-Christine Walz

given: Antje-Christine

family: Benz

full_name: Jörg Benz

given: Jörg

name: Roche Pharma Research & Early Development, Penzberg, Germany

family: Bujotzek

full_name: Alexander Bujotzek

given: Alexander

family: Lichtenegger

full_name: Felix S Lichtenegger

given: Felix S

family: Gassner

full_name: Christian Gassner

family: Carpy

full_name: Alejandro Carpy

given: Alejandro

name: Nimble Therapeutics, Madison, Wisconsin, United States

name: National Center for Tumor Diseases, Partner Site Dresden, Dresden, Germany

name: German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

name: Helmholtz Zentrum München, Munich, Germany

name: GLYCART Biotechnology AG, Zurich, Switzerland

ipd_sharing_description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

location_country: Italy Germany France Australia Spain Denmark Canada Taiwan

location_facility: National Cheng Kung University Hospital; Oncology

location_facility: Hospital Universitari Vall d'Hebron; Servicio de Hematologia

location_facility: Hospital Universitario la Fe; Servicio de Hematologia

location_facility: National Taiwan Universtiy Hospital; Division of Hematology

location_facility: Institut Catala d´Oncologia Hospital Germans Trias i Pujol

location_facility: Ospedale Santa Chiara; Unita Operativa Di Ematologia

location_facility: Hospital Clínic i Provincial; Servicio de Hematología y Oncología

location_facility: Hospital Univ. 12 de Octubre; Servicio de Hematologia

location_facility: Institut Paoli Calmettes; Departement D' Onco-Hematologie

location_facility: Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III

location_facility: China Medical University Hospital; Oncology and Hematology

location_facility: Peter MacCallum Cancer Centre; Medical Oncology

location_facility: Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia


title: Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3)

summary: This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+ posttransplant lymphoproliferative disorders (PTLD). However, responders to rituximab achieving a CR after the first 4 applications of rituximab will go on with rituximab monotherapy and will not receive chemotherapy.

ReferenceCitation: Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19.

name: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe...

family: Trappe

full_name: Ralf U. Trappe

given: Ralf U.

family: Dierickx

full_name: Daan Dierickx

given: Daan

family: Zimmermann

full_name: Heiner Zimmermann

given: Heiner

family: Morschhauser

full_name: Franck Morschhauser

given: Franck

family: Mollee

full_name: Peter Mollee

given: Peter

family: Zaucha

full_name: Jan M. Zaucha

given: Jan M.

family: Dreyling

full_name: Martin H. Dreyling

given: Martin H.

family: Dührsen

full_name: Ulrich Dührsen

given: Ulrich

family: Reinke

full_name: Petra Reinke

given: Petra

family: Verhoef

full_name: Gregor Verhoef

given: Gregor

family: Subklewe

full_name: Marion Subklewe

given: Marion

family: Hüttmann

full_name: Andreas Hüttmann

given: Andreas

family: Tousseyn

full_name: Thomas Tousseyn

given: Thomas

family: Salles

full_name: Gilles Salles

given: Gilles

family: Kliem

full_name: Volker Kliem

given: Volker

family: Hauser

full_name: Ingeborg A. Hauser

given: Ingeborg A.

family: Tarella

full_name: Corrado Tarella

given: Corrado

family: Van Den Neste

full_name: Eric Van Den Neste

given: Eric

family: Gheysens

full_name: Olivier Gheysens

given: Olivier

family: Anagnostopoulos

full_name: Ioannis Anagnostopoulos

given: Ioannis

family: Leblond

full_name: Veronique Leblond

given: Veronique

family: Riess

full_name: Hanno Riess

given: Hanno

family: Choquet

full_name: Sylvain Choquet

given: Sylvain

repository_institution: The University of Queensland - Queensland's institutional digital repository

publisher: American Society of Clinical Oncology (ASCO)

location_country: Italy Sweden France Poland Belgium Australia Germany

location_facility: Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Hematology and Oncology, Augustenburger Platz 1

location_facility: Zakład Propedeutyki Onkologii, Gdańskiego Uniwersytetu Medycznego

location_facility: Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, Qld 4102

location_facility: Sahlgrens hospital, Department of Hematology

location_facility: Div. Universitaria Ematologia e Terapie Cellulari, University of Torino

location_facility: Hôpital Pitié-Salpétrière, Department of Hematology, 47-83 Boulevard de l'Hopital

location_facility: Catholic University of Leuven, Department of Hematology


title: A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

summary: To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

ipd_sharing: Yes

ipd_sharing_description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

lead_sponsor: Amgen

location_country:
Austria
Netherlands
Germany
France
Japan
Spain
United States
Korea, Republic of
Taiwan

location_facility: Klinikum der Universität München Campus Grosshadern

location_facility: Universitaetsklinikum Hamburg Eppendorf Onkologisches Zentrum

location_facility: Severance Hospital Yonsei University Health System

location_facility: Hospital Clinico Universitario de Valencia

location_facility: University of California at Irvine Medical Center

status_simplified: Ongoing


title: An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Fabry Subjects With Amenable GLA Variants and Severe Renal Impairment

summary: This is an Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Fabry Subjects With Amenable GLA Variants and Severe Renal Impairment

study_start_date_type: Anticipated

status: Not yet recruiting

lead_sponsor: Amicus Therapeutics

location_country:
Italy
France
Belgium
Spain
United States
United Kingdom

location_facility: Internal Medicine Unit Croix Saint Simon Hospital

location_facility: Hospital General Universitario Gregorio Marañon

location_facility: Azienda Ospedalira Universitaria CAREGGI S.O.D.c. Nefrologia Dialisi Trapianto


title: A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving

summary:
The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder.

The secondary objectives are:

to assess the effect of rimonabant on the number of binge episodes per week, to assess the effect of rimonabant on eating behavior using the Binge Eating Scale (BES) and Three Factor Eating Questionnaire (TFEQ),
to evaluate the safety and tolerability of rimonabant over a period of 6 months.

ReferenceCitation: Pataky Z, Gasteyger C, Ziegler O, Rissanen A, Hanotin C, Golay A. Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):20-6. doi: 10.1055/s-0032-1329957. Epub 2012 Nov 12.

name: Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, World Health Organization Collaborating Centre, University Hospitals of Geneva, Geneva, Switzerland

family: Pataky

full_name: Z. Pataky

given: Z.

family: Gasteyger

full_name: C. Gasteyger

given: C.

name: Department of Diabetes, Metabolic and Nutritional Diseases, Jeanne d'Arc Hospital, Nancy University Hospitals, Nancy, France

family: Ziegler

full_name: O. Ziegler

given: O.

name: Obesity Research Unit, Helsinki University Central Hospital, Helsinki, Finland

family: Rissanen

full_name: A. Rissanen

given: A.

family: Hanotin

full_name: C. Hanotin

family: Golay

full_name: A. Golay

journal_name: Experimental and Clinical Endocrinology & Diabetes

publisher: Georg Thieme Verlag KG

publisher_dissemination: Georg Thieme

publisher_group: Georg Thieme

publisher_normalized: Georg Thieme

location_country:
Sweden
Switzerland
Netherlands
Finland
France
Portugal
United States


title: Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/Day or 20mg/Day, Versus Placebo, as an Aid to Smoking Cessation; Multiple Country, Randomized, Double-blind, 3-arm, 10-week Treatment, 40-week Follow-up

acronym: STRATUS-EU

summary:
The primary objective is to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers.

The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period and to observe the percentage of abstinent subjects during a 40-week follow-up post treatment.

location_country:
Sweden
Switzerland
France
Belgium
Spain
Denmark
United Kingdom


title: Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study

summary:
New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease. In this case certain fat molecules are not digested and broken down by the body - but remain in the cells. These fat molecules build up to dangerous levels, which start to damage the body, because they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a stroke.

The purpose of this study is to investigate the stroke rehabilitation of Fabry patients during different therapeutic standard approaches for stroke and for Fabry disease (if any). During this study, stroke patients with Fabry disease will be monitored in greater detail to determine whether the differences in treatment are significant for patient recovery and on what they depend.

ReferenceCitation: Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005 Nov 19;366(9499):1794-6. Erratum in: Lancet. 2006 Dec 23;368(9554):2210.

ipd_sharing: Undecided

lead_sponsor: CENTOGENE GmbH Rostock

location_country: Austria Croatia France Poland Georgia Portugal Germany

location_facility: University of Giessen-Marburg Dept. of Neurology

location_facility: Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf

location_facility: Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires

location_facility: Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university

location_facility: Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH

location_facility: Department of Neurology, Universitaetsklinikum Carl Gustav Carus

location_facility: Department of Neurology, University Tuebingen

location_facility: Department of Neurology, Universitaetsklinikum Jena

location_facility: Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology

location_facility: Centro Hospitalar de Lisboa Central, Servico de Neurologia

location_facility: Heinrich-Heine-University Duesseldorf, Dept. of Neurology

location_facility: Charite Campus Benjamin Franklin, Dept. of Neurology

location_facility: Department of Neurology, Klinikum Chemnitz gGmbH

location_facility: Institute of Psychiatry and Neurology, Dept. of Neurology

location_facility: Department of Neurology, Universitaetsklinikum Leipzig

location_facility: Department of Neurology, Allgemeines Krankenhaus Celle

location_facility: University of Ulm, Department of Neurology

location_facility: Department of Neurology, Klinikum Hohe Warte

location_facility: Department of Neurology, University Hospital Sestre Milosrdnice

intervention_type: Other


title: A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.

acronym: VEGA

summary:
The purpose of the study is to evaluate the efficacy and safety of SR58611A (350 mg BID) compared to placebo in the prevention of relapse of anxiety, in patients with Generalized Anxiety Disorder improved after 12 weeks of treatment with SR58611A.

The primary objective is to evaluate the efficacy of SR58611A 350mg BID compared to placebo over a 24 to 52-week treatment period.

The secondary objective is to assess the safety and tolerability of SR58611A in patients with GAD.

location_country:
Italy
Chile
Mexico
France
Hungary
Australia
Russian Federation
Spain
Germany


title: A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease

summary:
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. Prior to this study a pilot phase I (part I) determined the optimal dose by assessing the safety and tolerability of 2 dose levels in each arm. The optimal dose was administered in the Part II study. Participants who received the optimal dose in each treatment arm in Part I were included in the Part II analysis population.

Primary objective:

To assess the time to progression (TTP) of Docetaxel in combination with Oxaliplatin with or without 5-Fluorouracil (5-FU) or Capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease (part II).

Secondary objectives:

To establish the safety profile.
To assess the Overall Response Rate (ORR) based on the World Health Organization (WHO) criteria
To assess the Overall Survival (OS)

ReferenceCitation: Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015 Jan;26(1):149-156. doi: 10.1093/annonc/mdu496.

family: Van Cutsem

full_name: E. Van Cutsem

given: E.

family: Boni

full_name: C. Boni

family: Tabernero

full_name: J. Tabernero

given: J.

family: Massuti

full_name: B. Massuti

given: B.

family: Middleton

full_name: G. Middleton

given: G.

family: Dane

full_name: F. Dane

given: F.

family: Reichardt

full_name: P. Reichardt

given: P.

family: Pimentel

full_name: F.L. Pimentel

family: Cohn

full_name: A. Cohn

family: Follana

full_name: P. Follana

family: Clemens

full_name: M. Clemens

given: M.

family: Zaniboni

full_name: A. Zaniboni

family: Moiseyenko

full_name: V. Moiseyenko

given: V.

family: Harrison

full_name: M. Harrison

family: Richards

full_name: D.A. Richards

family: Prenen

full_name: H. Prenen

given: H.

family: Pernot

full_name: S. Pernot

given: S.

family: Ecstein-Fraisse

full_name: E. Ecstein-Fraisse

family: Hitier

full_name: S. Hitier

family: Rougier

full_name: P. Rougier

journal_name: Annals of Oncology

oa_host_type: publisher

license: elsevier-specific: oa user license

license_normalized: elsevier-specific

location_country:
Italy
United States
Switzerland
Spain
France
Hungary
Belgium
Russian Federation
Portugal
Turkey
Germany
United Kingdom


title: Investigating Bone Density and Bone Loss Without Baseline Information

summary:
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.

PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women with breast cancer receiving treatment in clinical trial IBCSG-1-98.

ReferenceCitation: Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat. 2014 Apr;144(2):321-9. doi: 10.1007/s10549-014-2849-2. Epub 2014 Feb 1.

family: DeCensi

full_name: Andrea DeCensi

given: Andrea

family: Sun

full_name: Zhuoxin Sun

given: Zhuoxin

family: Guerrieri-Gonzaga

full_name: Aliana Guerrieri-Gonzaga

given: Aliana

family: Thürlimann

full_name: Beat Thürlimann

given: Beat

family: McIntosh

full_name: Christina McIntosh

given: Christina

family: Tondini

full_name: Carlo Tondini

given: Carlo

family: Monnier

full_name: Alain Monnier

given: Alain

family: Campone

full_name: Mario Campone

given: Mario

family: Debled

full_name: Marc Debled

given: Marc

family: Schönenberger

full_name: Astrid Schönenberger

given: Astrid

family: Zaman

full_name: Khalil Zaman

given: Khalil

family: Johansson

full_name: Harriet Johansson

given: Harriet

family: Price

full_name: Karen N. Price

given: Karen N.

family: Gelber

full_name: Richard D. Gelber

given: Richard D.

family: Goldhirsch

full_name: Aron Goldhirsch

given: Aron

family: Coates

full_name: Alan S. Coates

given: Alan S.

family: Aebi

full_name: Stefan Aebi

given: Stefan

journal_name: Breast Cancer Research and Treatment

oa_host_type: repository

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer

publisher_group: Springer

publisher_normalized: Springer

location_country:
Italy
South Africa
Peru
Switzerland
France
Australia
New Zealand
Spain

location_facility: Centre Hospitalier Universitaire Vaudois

location_facility: Institute of Oncology at Prince of Wales Hospital

location_facility: Instituto Nacional de Enfermedades Neoplasicas

location_facility: Centro di Riferimento Oncologico - Aviano


title: 2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)

summary:
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating older patients with previously untreated B-cell lymphoma.

lead_sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

location_country:
Italy
Sweden
Switzerland
Netherlands
France
Czechia
Poland
Germany
United Kingdom

location_facility: Praxis fuer Haematologie und Internistische Onkologie - Borken

location_facility: Gemeinschaftspraxis feur Haemotologie und Onkologie - Weilheim

location_facility: Medizinische Universitaetsklinik I at the University of Cologne

location_facility: Burkhard and Reimann Gemeinschaftspraxis

location_facility: Praxis Internistischer Onkologie und Haematologie - Frechen

location_facility: Universitaetsklinikum Schleswig-Holstein - Campus Luebeck

location_facility: Kliniken der Stadt Koeln gGmbH - Krankenhaus Holweide

location_facility: Privatklinik Dr. R. Schindlbeck GmbH & Co. KG

location_facility: Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie

location_facility: Schwerpunktpraxis Haematologie/Onkologie - Hannover

location_facility: Klinikum der Stadt Ludwigshafen am Rhein

location_facility: St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH

location_facility: Praxis fuer Haematologie und Interne Onkologie

location_facility: Klinikum der Friedrich-Schiller Universitaet Jena

location_facility: Praxis fuer Onkologie am Diakonissenhaus

location_facility: Schwerpunktpraxis fuer Haematologie und Onkologie - Luebeck

location_facility: Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

location_facility: Sophien - und Hufeland - Klinikum Weimar gGmbH

location_facility: Praxis Internistischer Onkologie und Haematologie - Koeln

location_facility: Klinikum Barnim GmbH, Werner Forssmann Krankenhaus

location_facility: Gemeinschaftspraxis fuer Internistische - Frankenthal

location_facility: Gemeinschaftspraxis fuer Dres. Aldaoud und Schwarzer

location_facility: Krankenhaus St. Elisabeth und St. Barbara

location_facility: Krankenanstalt Mutterhaus der Borromaerinnen

location_facility: Praxis Dr. Rheinhold Siegmund - Dr. Matthias Penke

location_facility: Internistisch-Haematologische Gemeinschaftspraxis - Gustrow

location_facility: Onkologische Schwerpunktpraxis Dr. med. Verpoort, PD Dr. med. Zeller and Dr. med. Wierecky

location_facility: Gemeinschaftspraxis fuer Onkologie - Nordhorn

location_facility: Praxisklinik fuer Innere Medizin - Nuernberg

location_facility: Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock

location_facility: Praxis fur Innere Medizin - Schmiedeberg

location_facility: Haematologie und Internistische Onkologie Praxis

location_facility: Krankenhaus Barmherzige Brueder Regensburg

location_facility: Praxis Fuer Internistische Haematologie / Onkologie

location_facility: Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg

location_facility: Krankenhaus Hohe Warte Mediziniche Klinik

location_facility: Klinik fuer Onkologie - Katharinenhospital Stuttgart

location_facility: Schwerpunktpraxis fuer Haematologie und Onkologie - Flensburg

location_facility: Gastroenterologische und Haematologisch-Onkologische Praxis E. M. Dr. Hoering von Ehr Respondek

location_facility: Onkologische Schwerpunktpraxis - Straubing

location_facility: Helios Kliniken Wuppertal University Hospital

location_facility: Haematologische / Onkologische Schwerpunktpraxis

location_facility: Internistische Gemeinschaftspraxis - Berlin

location_facility: University Medical Center Hamburg - Eppendorf

location_facility: Universitaetsklinikum Giessen und Marburg GmbH - Marburg

location_facility: Internistische Gemeinschaftspraxis - Offenbach

location_facility: Gemeinschaftspraxis fuer Haematologie und Internist - Schweinfurt

location_facility: Internistische Gemeinschaftspraxis - Halle

location_facility: Marienhospital at Ruhr University Bochum

location_facility: Onkologische Schwerpunktpraxis Dr. Schmidt

location_facility: Internistische Gemeinschaftspraxis - Jena

location_facility: Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

location_facility: Internistische Gemeinschaftspraxis - Oldenburg

location_facility: Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster

location_facility: Regional Hospital Am Plattenwald Bad Friedrichshall

location_facility: Praxis Fuer Haematologie Internistische Onkologie

location_facility: St. Johannes Hospital - Medical Klinik II

location_facility: Staedtisches Klinikum Magdeburg - Altstadt

location_facility: Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH

location_facility: Medizinische Poliklinik, Universitaet Wuerzburg

location_facility: Onkologische Gemeinschaftspraxis - Kaiserslautern

location_facility: Robert Roessle Comprehensive Cancer Center - Charite Campus Buch

location_facility: Evangelisches Krankenhaus - Lutherstadt Wittenberg

location_facility: Onkologische Schwerwpunktpraxis Dr. Ladda

location_facility: Onkologische Schwerpunktpraxis und Tagesklinik Dres

location_facility: Clinic for Bone Marrow Transplantation and Hematology and Oncology

location_facility: Haematologische/Onkologische Schwerpunktpraxis - Rostock

location_facility: University Leipzig Clinic of Internal Medicine

location_facility: Staedtisches Krankenhaus Muenchen - Harlaching

location_facility: St. Marien Hospital - Muelheim an der Ruhr

location_facility: Praxis fuer Innere Medizin am Krankenhaus Siloah - Pforzheim

location_facility: Internistische Onkologische Praxis - Kronach

location_facility: Krankenhaus Martha-Maria Halle-Doelau gGmbH

location_facility: Internistische Praxis Dres. Hempel und Hochdorfer

location_facility: Praxis fuer Haematologie und Onkologie - Burgwedel

location_facility: Medizinische Klinik III - Universitaetsklinikum Erlangen

location_facility: Internistische Gemeinschaftspraxis - Kassel

location_facility: Haematologische Praxis - Moenchengladbach

location_facility: Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm

location_facility: Ruprecht - Karls - Universitaet Heidelberg

location_facility: Klinikum Rechts Der Isar - Technische Universitaet Muenchen

location_facility: Schwerpunktpraxis Internist Onkologie - Marburg

location_facility: Internistische Gemeinschaftspraxis - Magdeburg

location_facility: Onkologische Schwerpunktpraxis - Villingen

location_facility: Onkologische Gemeinschaftspraxis - Trier

location_facility: St. Marienkrankenhaus - Frankfurt am Main

location_facility: Klinikum der Universitaet Muenchen - Grosshadern Campus

location_facility: Medizinische Klinik am Lukas - Krankenhaus

location_facility: Krankenhaus Siloah - Medizinische Klinik II

location_facility: Gemeinschaftspraxis Dres. med. Ellbrueck/Goeller/Kraenzle/Niedermeier/Jocham

location_facility: Klinikum Schwaebisch Gmuend Stauferklinik

location_facility: Gemeinschaftspraxis fuer Haematologie - Northeim

location_facility: Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet

location_facility: Haematologisch - Onkologische Gemeinschaftspraxis - Muenster